A Study of ARQ 197 in Combination With Erlotinib

A Phase I Study of ARQ 197 in Combination With Erlotinib in CYP2C19 Poor Metabolizer Patients With Advanced/Recurrent Non-Small-Cell Lung Cancer

NCT01251796•Kyowa Kirin Co., Ltd.

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Advanced/Recurrent Non-small-cell Lung Cancer

Interventions

ARQ 197 and Erlotinib

Locations

Japan

Locations (1)

Shizuoka, Japan

Key Dates

Start Date

December 1, 2010

Primary Completion Date

November 1, 2012

Completion Date

November 1, 2012

Last Updated

March 15, 2017

Sponsors

Lead Sponsor

Kyowa Kirin Co., Ltd.

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 15, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions